How much profit has IRLAB Therapeutics made this year?
IRLAB Therapeutics has made -88.48 M SEK this year.
IRLAB Therapeutics Net Income 2024
IRLAB Therapeutics Net Income
-88.48 M SEK
Ticker
IRLAB A.ST
ISIN
SE0012675361
WKN
A2PLBE
In 2024, IRLAB Therapeutics's profit amounted to -88.48 M SEK, a -50.25% increase from the -177.84 M SEK profit recorded in the previous year.
The IRLAB Therapeutics Net Income history
| YEAR | NET INCOME (undefined SEK) |
|---|---|
| 2029e | - |
| 2028e | - |
| 2027e | - |
| 2026e | -118.33 |
| 2025e | -12.68 |
| 2024e | -88.48 |
| 2023 | -177.84 |
| 2022 | -113.41 |
| 2021 | 51.78 |
| 2020 | -91.65 |
| 2019 | -96.12 |
| 2018 | -74.1 |
| 2017 | -56.23 |
| 2016 | -42.7 |
| 2015 | -11.89 |
IRLAB Therapeutics Revenue, EBIT, Net Income SE0012675361 · A2PLBE
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into IRLAB Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by IRLAB Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects IRLAB Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of IRLAB Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into IRLAB Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing IRLAB Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on IRLAB Therapeutics’s growth potential.
IRLAB Therapeutics Revenue, EBIT and net profit per share
| Date | IRLAB Therapeutics Revenue | IRLAB Therapeutics EBIT | IRLAB Therapeutics Net Income |
|---|---|---|---|
| 2029e | 901.46 M undefined | 0 undefined | 0 undefined |
| 2028e | 661.84 M undefined | 595.68 M undefined | 0 undefined |
| 2027e | 417.76 M undefined | 346.68 M undefined | 0 undefined |
| 2026e | 90.78 M undefined | -118.32 M undefined | -118.33 M undefined |
| 2025e | 350.37 M undefined | 38.39 M undefined | -12.68 M undefined |
| 2024e | 123.62 M undefined | -86.91 M undefined | -88.48 M undefined |
| 2023 | 5.68 M undefined | -180.77 M undefined | -177.84 M undefined |
| 2022 | 61.14 M undefined | -113.11 M undefined | -113.41 M undefined |
| 2021 | 207.78 M undefined | 52.58 M undefined | 51.78 M undefined |
| 2020 | 0 undefined | -91.46 M undefined | -91.65 M undefined |
| 2019 | 26,000 undefined | -95.85 M undefined | -96.12 M undefined |
| 2018 | 18,000 undefined | -73.9 M undefined | -74.1 M undefined |
| 2017 | 109,000 undefined | -54.22 M undefined | -56.23 M undefined |
| 2016 | 144,000 undefined | -46.05 M undefined | -42.7 M undefined |
| 2015 | 0 undefined | -27.61 M undefined | -11.89 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2015 | 0 SEK | -27.61 M SEK | -11.89 M SEK |
| 2016 | 144,000 SEK | -46.05 M SEK | -42.7 M SEK |
| 2017 | 109,000 SEK | -54.22 M SEK | -56.23 M SEK |
| 2018 | 18,000 SEK | -73.9 M SEK | -74.1 M SEK |
| 2019 | 26,000 SEK | -95.85 M SEK | -96.12 M SEK |
| 2020 | 0 SEK | -91.46 M SEK | -91.65 M SEK |
| 2021 | 207.78 M SEK | 52.58 M SEK | 51.78 M SEK |
| 2022 | 61.14 M SEK | -113.11 M SEK | -113.41 M SEK |
| 2023 | 5.68 M SEK | -180.77 M SEK | -177.84 M SEK |
| 2024e | 123.62 M SEK | -86.91 M SEK | -88.48 M SEK |
| 2025e | 350.37 M SEK | 38.39 M SEK | -12.68 M SEK |
| 2026e | 90.78 M SEK | -118.32 M SEK | -118.33 M SEK |
| 2027e | 417.76 M SEK | 346.68 M SEK | 0 SEK |
| 2028e | 661.84 M SEK | 595.68 M SEK | 0 SEK |
| 2029e | 901.46 M SEK | 0 SEK | 0 SEK |
IRLAB Therapeutics stock margins SE0012675361 · A2PLBE
The IRLAB Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of IRLAB Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for IRLAB Therapeutics.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the IRLAB Therapeutics's sales revenue. A higher gross margin percentage indicates that the IRLAB Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the IRLAB Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the IRLAB Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the IRLAB Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the IRLAB Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the IRLAB Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
IRLAB Therapeutics Margin History
| IRLAB Therapeutics Gross margin | IRLAB Therapeutics Profit margin | IRLAB Therapeutics EBIT margin | IRLAB Therapeutics Profit margin |
|---|---|---|---|
| 2029e | -2,161.57 % | 0 % | 0 % |
| 2028e | -2,161.57 % | 90 % | 0 % |
| 2027e | -2,161.57 % | 82.99 % | 0 % |
| 2026e | -2,161.57 % | -130.34 % | -130.34 % |
| 2025e | -2,161.57 % | 10.96 % | -3.62 % |
| 2024e | -2,161.57 % | -70.31 % | -71.57 % |
| 2023 | -2,161.57 % | -3,183.6 % | -3,132.07 % |
| 2022 | -105.94 % | -185.01 % | -185.5 % |
| 2021 | 60.66 % | 25.3 % | 24.92 % |
| 2020 | -2,161.57 % | 0 % | 0 % |
| 2019 | -2,161.57 % | -368,646.14 % | -369,692.3 % |
| 2018 | -2,161.57 % | -410,538.9 % | -411,661.13 % |
| 2017 | -2,161.57 % | -49,742.21 % | -51,582.57 % |
| 2016 | -2,161.57 % | -31,981.25 % | -29,650 % |
| 2015 | -2,161.57 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2015 | -2,161.57 % | 0 % | 0 % |
| 2016 | -2,161.57 % | -31,981.25 % | -29,650 % |
| 2017 | -2,161.57 % | -49,742.21 % | -51,582.57 % |
| 2018 | -2,161.57 % | -410,538.9 % | -411,661.13 % |
| 2019 | -2,161.57 % | -368,646.14 % | -369,692.3 % |
| 2020 | -2,161.57 % | 0 % | 0 % |
| 2021 | 60.66 % | 25.3 % | 24.92 % |
| 2022 | -105.94 % | -185.01 % | -185.5 % |
| 2023 | -2,161.57 % | -3,183.6 % | -3,132.07 % |
| 2024e | -2,161.57 % | -70.31 % | -71.57 % |
| 2025e | -2,161.57 % | 10.96 % | -3.62 % |
| 2026e | -2,161.57 % | -130.34 % | -130.34 % |
| 2027e | -2,161.57 % | 82.99 % | 0 % |
| 2028e | -2,161.57 % | 90 % | 0 % |
| 2029e | -2,161.57 % | 0 % | 0 % |
IRLAB Therapeutics Aktienanalyse
What does IRLAB Therapeutics do?
IRLAB Therapeutics AB was founded in Stockholm, Sweden in 2012 and is a biopharmaceutical company specializing in the development of drugs for neurodegenerative diseases. The company has an innovative business model based on the discovery, development, and commercialization of drug candidates for various diseases. The company specializes in developing new and effective treatment options for neurodegenerative diseases. IRLAB Therapeutics AB has an extensive network of partners, including scientific institutions, universities, and clinical trial centers. With this network, the company ensures that all research and development activities are conducted using the latest scientific and technological advancements. The company operates in two segments: research and development and commercialization. In the research and development segment, the company focuses on identifying and developing drugs for neurodegenerative diseases such as Parkinson's and Alzheimer's. The company works on a pipeline of drug candidates in various stages of development, using advanced technologies such as in-silico screening and in-vivo testing to identify and develop new drug candidates. The commercialization segment of the company mainly deals with the distribution of already approved drugs. The company specializes in bringing these medications to market in its target regions. The company is particularly focused on the drugs Systebol and IRL752. Systebol is a medication for the treatment of cold-like symptoms in pregnant women and is already approved in some countries around the world. IRL752 is a substance for the treatment of psychiatric disorders and is also marketed by IRLAB Therapeutics. The main product of IRLAB Therapeutics AB is currently P21, a drug candidate for the treatment of Parkinson's disease. This drug candidate is in phase II of clinical trials and has received Orphan Drug designation from both the FDA and EMA. The company regularly reports on the progress of the clinical trials and announces ongoing news about the results. IRLAB Therapeutics AB has a clear vision and mission based on providing innovative solutions for patients with neurodegenerative diseases. The company aims to improve the lives of millions of people worldwide through the development of new and effective medical solutions. The company relies on collaboration with global and regional partners and invests in advanced technologies to establish itself as an innovative and reliable partner in the pharmaceutical industry. IRLAB Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding IRLAB Therapeutics's Profit Margins
The profit margins of IRLAB Therapeutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of IRLAB Therapeutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating IRLAB Therapeutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
IRLAB Therapeutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When IRLAB Therapeutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about IRLAB Therapeutics stock
How has the profit developed compared to last year?
The profit has increased by -50.25% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does IRLAB Therapeutics publish its earnings?
IRLAB Therapeutics publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of IRLAB Therapeutics?
The profits of IRLAB Therapeutics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of IRLAB Therapeutics?
You can learn more about the earnings of IRLAB Therapeutics by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does IRLAB Therapeutics pay?
Over the past 12 months, IRLAB Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, IRLAB Therapeutics is expected to pay a dividend of 0 SEK.
What is the dividend yield of IRLAB Therapeutics?
The current dividend yield of IRLAB Therapeutics is .
When does IRLAB Therapeutics pay dividends?
IRLAB Therapeutics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of IRLAB Therapeutics?
IRLAB Therapeutics paid dividends every year for the past 0 years.
What is the dividend of IRLAB Therapeutics?
For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.
In which sector is IRLAB Therapeutics located?
IRLAB Therapeutics is assigned to the 'Health' sector.
Wann musste ich die Aktien von IRLAB Therapeutics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of IRLAB Therapeutics from 9/18/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 9/18/2024.
When did IRLAB Therapeutics pay the last dividend?
The last dividend was paid out on 9/18/2024.
What was the dividend of IRLAB Therapeutics in the year 2023?
In the year 2023, IRLAB Therapeutics distributed 0 SEK as dividends.
In which currency does IRLAB Therapeutics pay out the dividend?
The dividends of IRLAB Therapeutics are distributed in SEK.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von IRLAB Therapeutics
Our stock analysis for IRLAB Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IRLAB Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- IRLAB Therapeutics Revenue
- IRLAB Therapeutics Net Income
- IRLAB Therapeutics P/E
- IRLAB Therapeutics P/S
- IRLAB Therapeutics EBIT
- IRLAB Therapeutics Dividend
- IRLAB Therapeutics Stocks
- IRLAB Therapeutics Market capitalization
- IRLAB Therapeutics Debt
- IRLAB Therapeutics Liabilities
- IRLAB Therapeutics Equity
- IRLAB Therapeutics AAQS
- IRLAB Therapeutics Employees
- IRLAB Therapeutics ROE
- IRLAB Therapeutics ROA
- IRLAB Therapeutics ROCE
